Vertex Pharmaceuticals (VRTX) closed the latest trading day at $402.70, indicating a +0.84% change from the previous session's end. This change outpaced the S&P 500's 0.43% loss on the day. At the ...

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

The newly approved medicines in 2024 from Massachusetts companies range from a schizophrenia drug to a gene therapy for ...

The small miracles that 2024 brought to our lives lay the groundwork for new revolutionary treatments that are being prepared ...

Investors need to pay close attention to Vertex Pharmaceuticals (VRTX) stock based on the movements in the options market lately.

Robin - Sherwin Marauders Kanghong Pharmaceuticals Vice President, Chief Financial Officer and Secretary Zhong Jianjun received a regulatory letter for "illegal purchase of stocks" Vertex's triple ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Of the top news articles, Vertex Pharmaceuticals' suzetrigine garnered much attention as it's a promising new class of pain ...

Equities researchers at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals ...

12月19日，专注于罕见病治疗的药品开发公司Vertex ...

2024年，生物医药行业仍然没有走出资本寒冬，裁员潮此起彼伏。据Fierce ...